• Galera Therapeutics adopted amended and restated bylaws effective May 12, 2026, granting stockholders a right to act by written consent.
• Change aligns with a charter amendment filed May 12, 2026, following stockholder action at May 8, 2026 annual meeting.
• Separate charter amendment filed May 11, 2026, doubled authorized common shares to 400 million from 200 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-225174), on May 15, 2026, and is solely responsible for the information contained therein.